RT Journal Article
SR Electronic
T1 Prenatal Lead Exposure is Negatively Associated with the Gut Microbiome in Childhood
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.10.23289802
DO 10.1101/2023.05.10.23289802
A1 Eggers, Shoshannah
A1 Midya, Vishal
A1 Bixby, Moira
A1 Gennings, Chris
A1 Torres-Olascoaga, Libni A
A1 Walker, Ryan W.
A1 Wright, Robert O.
A1 Arora, Manish
A1 Téllez-Rojo, Martha María
YR 2023
UL http://medrxiv.org/content/early/2023/05/11/2023.05.10.23289802.abstract
AB Background Metal exposures are associated with gut microbiome (GM) composition and function, and exposures early in development may be particularly important. Considering the role of the GM in association with many adverse health outcomes, understanding the relationship between prenatal metal exposures and the GM is critically important. However, there is sparse knowledge of the association between prenatal metal exposure and GM later in childhood.Objectives This analysis aims to identify associations between prenatal lead (Pb) exposure and GM composition and function in children 9-11 years old.Methods Data come from the Programming Research in Obesity, Growth, Environment and Social Stressors (PROGRESS) cohort based in Mexico City, Mexico. Prenatal metal concentrations were measured in maternal whole blood drawn during the second and third trimesters of pregnancy. Stool samples collected at 9-11 years old underwent metagenomic sequencing to assess the GM. This analysis uses multiple statistical modeling approaches, including linear regression, permutational analysis of variance, weighted quantile sum regression (WQS), and individual taxa regressions, to estimate the association between maternal blood Pb during pregnancy and multiple aspects of the child GM at 9-11 years old, adjusting for relevant confounders.Results Of the 123 child participants in this pilot data analysis, 74 were male and 49 were female. Mean prenatal maternal blood Pb was 33.6(SE=2.1) ug/L and 34.9(SE=2.1) ug/L at second and third trimesters, respectively. Analysis suggests a consistent negative relationship between prenatal maternal blood Pb and the GM at age 9-11, including measures of alpha and beta diversity, microbiome mixture analysis, and individual taxa. The WQS analysis showed a negative association between prenatal Pb exposure and the gut microbiome, for both second and third trimester exposures (2Tβ=-0.17,95%CI=[-0.46,0.11]; 3Tβ=-0.17,95%CI=[-0.44,0.10]). Ruminococcus gnavus, Bifidobacterium longum, Alistipes indistinctus, Bacteroides caccae, and Bifidobacterium bifidum all had weights above the importance threshold from 80% or more of the WQS repeated holdouts in association with both second and third trimester Pb exposure.Discussion Pilot data analysis suggests a negative association between prenatal Pb exposure and the gut microbiome later in childhood; however, additional investigation is needed.Competing Interest StatementMA is an employee and equity holder of Linus Biotechnology Inc., a start-up company of Mount Sinai Health System. The company develops tools for the detection of autism spectrum disorder and related conditions. The following authors report no competing interests: SE, VM, CG, MB, LT, RWW, ROW, MT.Funding StatementThis work was supported by the National Institute of Environmental Health Sciences (K99ES032884, P30ES023515, R01ES013744).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee/IRB of Icahn School of Medicine at Mount Sinai gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study can be made accessible to researchers upon appropriate request with the following restrictions to ensure the privacy of human subjects. Note that access to the data is limited due to a data-sharing agreement approved by the IRB at Mount Sinai. Researchers interested in accessing PROGRESS data must send their resume/CV and CITI training certificates to the IRB chair, Ilene Wilets (Ilene.wilets{at}mssm.edu). They must also submit a data analysis plan to the Principal Investigators for PROGRESS; Robert O. Wright (robert.wright{at}mssm.edu), Martha Tellez-Rojo (mmtellez{at}insp.mx), and Andrea Baccarelli (andrea.baccarelli{at}columbia.edu). Once this process is completed, the PROGRESS data analyst, Nia McRae (nia.x.mcrae{at}mssm.edu), will send a de-identified dataset via Box, a secure data-sharing platform.